Addiction & Substance Use

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.

How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?

While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!

Inhalant use disorder is a form of substance use disorder characterized by the intentional inhalation of volatile substances for their psychoactive effects.

Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.

This book seeks to reduce the stigma surrounding teen pregnancy.

Learn more about the latest viral substance abuse trend.

In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.

Assisted outpatient treatment is not intended to replace comprehensive, easy-to-access, voluntary treatment. Here's why we need it, according to one expert.

When psychiatrists fully embrace psychopharmacological interventions as integral components of addiction treatment, patients can begin a journey toward sustainable recovery.

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

Cannabis use during adolescence can profoundly impact brain development.

Social media is here to stay, and its use must be a consideration in the treatment of psychiatric conditions, particularly substance use disorder and alcohol use disorder.

Learn more about cannabis use and social media addiction in this month's Special Report!

What influence do legislation and social-based decisions have on individual mental health, like in the case of drag performers?

The FDA has issued a complete response letter to Orexo for OX124, a high-dose naloxone nasal spray for opioid overdose reversal.

What is new in research on alcohol use disorder?

To expertly utilize polypharmacy, it is imperative that clinicians stay abreast of new literature, check for drug-drug interactions, and be aware of emerging trends in drug use.

Inhalant use disorder is characterized by the intentional inhalation of volatile substances for their psychoactive effects. Learn more about how to help manage this disorder.

An expert discusses this comorbidity, plus the effects of semaglutide and other GLP-1 agonists on this patient population.

The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

With cannabis legalization increasing in the United States, so too are the issues surrounding cannabis access, usage, and use disorders. State by state, take a peek at some of the issues and updates surrounding cannabis.

Here are highlights from the week in Psychiatric Times.

We're highlighting issues in addiction in our special Digital Supplement! Learn more here.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.